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Abstract
Background: The extent to which patients with COPD are receiving indicated treatment with medications to improve lung
function and recent trends in the use of these medications is not well documented in the United States. The objective of this
study was to examine trends in prescription medications for COPD among adults in the United States from 1999 to 2010.
Methods: We performed a trend analysis using data from up to 1426 participants aged $20 years with self-reported COPD
from six national surveys (National Health and Nutrition Examination Survey 1999–2010).
Results: During 2009–2010, the age-adjusted percentage of participants who used any kind of medication was 44.2%. Also
during 2009–2010, the most commonly used medications were short-acting agents (36.0%), inhaled corticosteroids (ICS)
(18.3%), and LABAs (16.7%). The use of long-acting beta-2 agonists (LABAs) (p for trend ,0.001), ICS (p for trend= 0.013)
increased significantly over the 12-year period. Furthermore, the use of tiotropium increased rapidly during this period (p for
trend ,0.001). For the years 2005–2010, the use of LABAs, ICS and tiotropium increased with age. Compared with whites,
Mexican Americans were less likely to use short-acting agents, LABAs, ICS, tiotropium, and any kind of COPD medication.
Among participants aged 20–79 years with spirometry measurements during 2007–2010, the use of any medication was
reported by 19.0% of those with a moderate/severe obstructive impairment and by 72.6% of those with self-reported COPD
and any obstructive impairment.
Conclusion: The percentages of adults with COPD who reported having various classes of prescription medications that
improve airflow limitations changed markedly from 1999–2000 to 2009–2010. However, many adults with COPD did not
report having recommended prescription medications.
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Introduction
Because of the chronic and often progressive nature of COPD,
treatment is paramount in reducing symptoms, improving quality
of life and health status, enhancing exercise capacity, slowing
deterioration of lung function, limiting exacerbations, and
prolonging the life of patients with COPD [1,2]. Management of
these patients encompasses several critical elements which include
1) reducing or preferably eliminating exposure to the offending
agent that caused COPD; 2) prescribing medications as indicated;
3) use of oxygen when indicated; 4) pulmonary rehabilitation; and
5) reducing exacerbations. Treatment options for prescription
medications directed at the underlying airflow limitation have
evolved over time; whereas the mainstay of treatment several
decades ago included primarily methylxanthines and short-acting
beta-2 agonists, treatment has gradually shifted to emphasize
increasingly the use of long-acting beta-2 agonists and inhaled
corticosteroids (ICS).
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As the therapeutic armamentarium of medications used to treat
COPD has expanded, guidelines concerning the use of these
agents have also changed [1,3]. Consequently, a current perspec-
tive on the use of medications used to treat COPD in the United
States is valuable in gauging the concordance between recom-
mended guidelines and indicators of clinical practice. Therefore,
the principal objective of this study was to examine the trend in the
usage of prescription medications used to treat the airflow
limitation in patient with COPD in national samples of adults
with COPD. As secondary objectives, we sought to examine
sociodemographic determinants of the usage of these medications
and to determine the percentage of participants with an airflow
limitation who were receiving treatment with medications for their
condition.
Methods
Ethics Statement
The present study used publically-available data and was
exempt from human subjects review.
The analyses in this study were conducted using six 2-year
cycles of data from the National Health and Nutrition Examina-
tion Survey (NHANES) NHANES 1999–2010. In each of these
cycles, a stratified multistage selection process was used to select a
national probability sample. Participants who agreed to participate
were interviewed in their homes and offered an opportunity to
attend an examination in the mobile examination center. Those
who agreed were asked to complete additional questionnaires, to
undergo various examinations, and to provide a blood sample in
the mobile examination center. Response rates for the interview
ranged from 78% to 84%, and response rates for the examination
ranged from 75% to 80%. Details about the surveys may be found
elsewhere [4,5].
A participant was defined with self-reported COPD if the survey
participant reported having been told that he or she had chronic
bronchitis and still had it or if he or she reported that he or she had
emphysema. Participants who reported not having been told that
they had either condition were defined as not having COPD.
During 2007–2010, participants in NHANES aged 6–79 years
were offered an opportunity to have spirometry. Participants were
asked to provide three acceptable maneuvers on Ohio 822/827
dry-rolling seal volume spirometers [6]. Detailed protocols for the
spirometric examination can be found elsewhere [6,7]. Only
results from quality spirometric efforts were used.
Equations derived from earlier NHANES III data (1988–1994)
were used to calculate the predicted forced expiratory volume in 1
second (FEV1) and forced vital capacity (FVC) [8]. We applied the
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
classification of COPD severity that is based on post-bronchodi-
lator spirometric results to pre-bronchodilator testing [2]. In
addition, we also defined a category of restrictive impairment
(FEV1/FVC$0.70 and FVC,80% predicted) for some analyses.
In addition, some analyses were conducted using FEV1 predicted
of ,60% and 60–,80% in accordance with the 2011 American
College of Physicians, American College of Chest Physicians,
American Thoracic Society, and European Respiratory Society
(ACP/ACCP/ATS/ERS) recommendations [1].
Participants who responded affirmatively were then asked to
report the medications that they were using and, when available,
to show the medication containers to the interviewer who could
record up to 20 medications. The following major groups of
medications were established: any short acting medication
Table 2. Selected characteristics, by self-reported chronic obstructive pulmonary disease status, National Health and Nutrition
Examination Survey 1999–2010.
Chronic obstructive pulmonary disease (%, SE) No chronic obstructive pulmonary disease (%, SE) P-value
Age (years)
20–39 17.2 (1.3) 40.3 (0.5) ,0.001
40–59 38.1 (1.7) 37.9 (0.4) 0.964
60+ 44.7 (1.6) 21.8 (0.5) ,0.001
Gender
Men 37.7 (1.7) 48.4 (0.2) ,0.001
Women 62.3 (1.7) 51.6 (0.2) ,0.001
Race or ethnicity
White 80.1 (1.7) 69.9 (1.3) ,0.001
African American 9.6 (1.0) 11.3 (0.7) 0.431
Mexican American 2.1 (0.3) 8.0 (0.6) ,0.001
Other 8.1 (1.3) 10.8 (0.8) 0.011
Education
,High school 32.2 (1.8) 19.3 (0.5) ,0.001
High school graduate 28.0 (1.5) 25.1 (0.5) 0.570
.High school 39.8 (1.8) 55.6 (0.8) ,0.001
Smoking status
Current 41.0 (1.8) 23.0 (0.5) ,0.001
Former 34.2 (1.6) 24.1 (0.5) ,0.001
Never 24.8 (1.4) 52.9 (0.6) ,0.001
Number of adults with COPD varied from 1424 to 1426. Number of participants without COPD varied from 30947 to 31034.
doi:10.1371/journal.pone.0095305.t002
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(albuterol, fenolterol, levalbuterol, metaprotenerol, pirbuterol,
terbutaline, ipratropium, fenolterol plus ipratropium, and albute-
rol plus ipratropium), long-acting beta-2 agonists (LABA) (salme-
terol, formoterol, and arformoterol whether used separately or as
part of a combination product), ICS (beclomethasone, budenoside,
flunisolide, fluticasone, and triamcinolone whether used separately
or as part of a combination product), short-acting anticholinergic
agents (ipratropium), long-acting anticholinergic agents (tiotro-
pium), methylxanthines (aminophylline and theophylline), and any
of the aforementioned medications.
Participants who responded affirmatively to one or more of
these questions were considered to have evidence of respiratory
symptoms. Because the question about shortness of breath was
asked only of participants aged $40 years, analyses involving
respiratory symptoms were limited to this age group.
To examine the sociodemographic variation in prescribed
medication use, we included the following covariates: age, gender,
self-reported race or ethnicity (white, African American, Mexican
American, and other), and educational level (less than 12 years,
high school graduate or equivalent, education beyond high
school).
The analyses were limited to participants aged $20 years for
analyses involving adults with self-reported COPD in 1999–2010,
to participants aged 20–79 years in 2007–2010 for analyses
involving spirometric data, and to participants aged 40–79 years
for analyses involving respiratory symptoms. Age-adjustment to
the projected year 2000 U.S. population was done with the direct
method using three age groups (20–39 years, 40–59 years, and $
60 years). Tests for linear trend were conducted using polynomial
orthogonal contrasts. In addition, we examined tests for linear
trend by calculating prevalence ratios adjusted for age, gender,
race or ethnicity, and educational status using log-binomial
models. To examine the most recent sociodemographic correlates
of medication use, we combined data for the years 2005–2010 to
increase sample size. We used SAS for data processing and
SUDAAN to account for the complex sampling design of the
survey and produce estimates (means and percentages) that are
representative of the civilian noninstitutionalized population in the
United States. Sample sizes provided in the text and tables
represent unweighted numbers.
Results
The numbers of participants aged $20 years who were
interviewed for the six consecutive cycles were 4880, 5411,
5041, 4979, 5935, and 6218, and the numbers of participants who
reported having been told that they had COPD were 213
(weighted percentage 4.2%), 208 (3.5%), 234 (4.3%), 212 (4.4%),
314 (4.3%), and 245 (3.3%). Medication status could be
ascertained for all but two participants. The sociodemographic
breakdown for these participants with COPD is shown in Table 1.
Based on aggregated data for the 12-year period, adults with self-
reported COPD were older, more likely to be women, to be white,
to be less educated, and to be a current smoker than adults without
COPD (Table 2).
Medication Use among Participants with Self-reported
COPD: NHANES 1999 to 2010
During 2009–2010, an unadjusted 53.2% (SE 4.9) of partici-
pants reported no medications used in the management of COPD,
21.1% (SE 3.4) reported a medication from one group, 16.9% (SE
2.9) reported medications from 2 groups, and 8.7% (SE 3.3)
reported medications from 3 or more groups. Averaged over all 12T
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years, 7.6% (SE 0.9) of participants used medications from 3 or
more groups.
During 2009–2010, an age-adjusted 44.2% of participants used
any type of prescription medication used to treat COPD (Table 3).
In descending order of reported use were short-acting agents
(36.0%) consisting primarily short-acting beta-2 agonists (SABA)
(31.3%), ICS whether alone or in combination with a LABA
(18.3%), LABAs whether alone or in combination with an inhaled
corticosteroid (16.7%), tiotropium (10.5%), and methylxanthines
(,2.0%). The trend in the use of any medication increased
significantly during the study period. The relatively high use of
medications during 1999–2000 was a function of the high use of
short-acting agents. Significant increases were noted for the use of
LABAs, ICS, tiotropium, and any medication. The data also
Table 4. Adjusted prevalence ratios* (95% confidence interval) for use of prescription medications used to treat chronic
obstructive pulmonary disease among 770 adults aged $20 years with self-reported chronic obstructive pulmonary disease,
National Health and Nutrition Examination Survey 2005–2010.
Any short-acting
agent{
Any inhaled long-acting
beta-2 agonists`
Any inhaled
corticosteroid1 Tiotropium Any medication
Number using medication 253 129 153 65 318
Age (years)
20–39 1.00 1.00 1.00 1.00 1.00
40–59 1.01 (0.70, 1.48) 1.26 (0.61, 2.61) 1.43 (0.76, 2.68) 7.49 (1.45, 38.70) 1.08 (0.76, 1.52)
60+ 1.01 (0.70, 1.47) 1.78 (0.98, 3.23) 1.92 (1.10, 3.34) 9.26 (2.08, 41.10) 1.24 (0.87, 1.77)
Gender
Men 1.03 (0.77, 1.37) 0.89 (0.59, 1.37) 0.88 (0.58, 1.34) 0.95 (0.48, 1.87) 1.06 (0.82, 1.37)
Women 1.00 1.00 1.00 1.00 1.00
Race or ethnicity
White 1.00 1.00 1.00 1.00 1.00
African American 1.16 (0.88, 1.54) 1.02 (0.63, 1.67) 1.04 (0.63, 1.71) 0.81 (0.30, 2.22) 1.08 (0.82, 1.42)
Mexican American 0.37 (0.15, 0.89) 0.33 (0.12, 0.90) 0.33 (0.15, 0.70) 0.14 (0.02, 0.97) 0.36 (0.18, 0.72)
Other 1.24 (0.88, 1.76) 1.48 (0.84, 2.61) 1.28 (0.79, 2.06) 0.81 (0.33, 2.00) 1.08 (0.78, 1.49)
Education
,High school 1.19 (0.87, 1.61) 1.36 (0.85, 2.19) 1.30 (0.89, 1.91) 2.17 (1.02, 4.63) 1.20 (0.91, 1.58)
High school graduate 1.16 (0.88, 1.53) 1.27 (0.70, 2.30) 0.89 (0.51, 1.53) 1.29 (0.59, 2.84) 1.08 (0.84, 1.40)
.High school 1.00 1.00 1.00 1.00 1.00
*Prevalence ratios are adjusted for all variables shown in table.
{Albuterol, fenolterol, levalbuterol, metaprotenerol, pirbuterol, terbutaline, ipratropium.
`Salmetrol, formoterol, arformoterol.
1Beclomethasone, budenoside, flunisolide, fluticasone, triamcinolone.
doi:10.1371/journal.pone.0095305.t004
Table 5. Age-adjusted percentages (standard error) of adults aged 20–79 years taking prescription medications for chronic
obstructive pulmonary disease defined by spirometry, by Global Initiative for Chronic Obstructive Lung Disease status, National
Health and Nutrition Examination Survey 2007–2010.
Normal Mild OI $Moderate/severe OI
N* 6293 580 491
Any short-acting agent{ 2.2 (0.2) –" 15.5 (2.4)
Any inhaled long-acting beta-2 agonists` 1.1 (0.2) –" 6.5 (1.5)
Any inhaled corticosteroid1 1.6 (0.2) –" 9.0 (2.0)
Tiotropium –" –" –"
Methylxanthines? –" –" –"
Any medication for COPD 3.1 (0.3) 7.3 (2.2)" 19.0 (2.7)
OI = obstructive impairment.
*Sample sizes represent unweighted numbers.
{Albuterol, fenolterol, levalbuterol, metaprotenerol, pirbuterol, terbutaline, ipratropium.
`Salmetrol, formoterol, arformoterol.
1Beclomethasone, budenoside, flunisolide, fluticasone, triamcinolone.
?Aminophylline, theophylline.
"Relative standard error $30%.
doi:10.1371/journal.pone.0095305.t005
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suggested that the use of ICS as single agents decreased whereas
the use of combination products of LABAs and corticosteroids
increased (data not shown).
Even after combining six years of data, the numbers of
participants in the 2005–2010 time period who reported using
various types of medications was limited resulting in reduced
power to examine sociodemographic correlates of medication use
(Table 4). The use of ICS and tiotropium increased among
successive age groups in 2005–2010. Compared with whites,
Mexican Americans were less likely to use short-acting agents,
LABAs, ICS, tiotropium, and any kind of COPD medication
(Table 4).
After combining 12 years of data for participants aged $40
years with self-reported COPD, 87.1% (SE 1.5) of participants
who did not use medications to treat COPD and 95.2% (SE 1.3) of
those who used such medications reported having one or more of
the following symptoms: cough, phlegm, wheezing, and shortness
of breath.
Medication Use among Participants with an Obstructive
Impairment: NHANES 2007 to 2010
Of the 11289 participants aged 20–79 years who were
interviewed in 2007–2010, 10981 attended the mobile examina-
tion center and 9047 had values for FEV1 and FVC, allowing
their lung function status to be established for 7887 participants
with adequate spirometric efforts: 580 participants with a mild
obstructive impairment, 428 with a moderate obstructive impair-
ment, and 63 with a severe obstructive impairment. Because of the
small number of participants with a severe obstructive impairment,
they were combined with participants who had a moderate
obstructive impairment.
The prevalence of self-reported COPD was 3.7% and that of
any obstructive impairment was 13.4% (7.6% mild obstructive
impairment, 5.8% moderate or worse obstructive impairment). Of
adults with any obstructive impairment based on spirometry, 7.5%
had self-reported COPD, and among adults with self-reported
COPD, 34.8% had evidence of an obstructive impairment. The
use of any COPD medication was reported by 7.3% (SE 2.2) of
participants with a mild obstructive impairment and 19.0% (SE
2.7) of participants with a moderate/severe obstructive impair-
ment (Table 5). Among those with a moderate/severe obstructive
impairment, the most commonly reported medications were short-
acting agents (15.5%), followed by ICS (9.0%), and LABAs (6.5%).
Tiotropium and methylxanthines were used by small percentages
of participants (#2%).
Over 70% of participants with an obstructive impairment and
with self-reported COPD reported using any COPD medication,
the majority of which were short-acting agents (Table 6). In
comparison, almost 30% of adults without an obstructive
impairment but with self-reported COPD used a medication.
In an attempt to assess the percentage of participants with
COPD who reported using medications consistent with the 2011
ACP/ACCP/ATS/ERS recommendations, we stratified medica-
tions use by self-reported COPD status, presence or absence of
respiratory symptoms, and percent FEV1 predicted (Table 7).
Although the use of long-acting medications (31.5% among
participants with an FEV1 predicted 60% to 80% and 53.8% of
participants with an FEV1 predicted ,60%) and any medications
(46.2% among participants with an FEV1 predicted 60% to 80%
and 72.8% of participants with an FEV1 predicted ,60%)
increased as FEV1% predicted decreased among participants with
self-reported COPD and symptoms, substantial percentages of
these participants did not report using such medications.
Discussion
Our analyses highlight several findings of interest. First, the
types of medications that adults with self-reported COPD reported
using changed substantially from 1999 to 2010. In particular, the
use of LABAs, inhaled corticosteroids, and tiotropium increased
sharply. Second, Mexican American adults with self-reported
COPD were less likely to report using the different medications
that we examined than white adults. Third, many adults with
COPD were not receiving potentially beneficial treatment.
Although important changes in medications to treat COPD
have occurred during the last decade, the trends in the use of these
medications in the United States have not been adequately
documented in the medical literature. The Food and Drug
Administration approved several medications during the past
decade including the combination of salmeterol and fluticasone in
2000, tiotropium in 2004, and the combination of formoterol and
Table 6. Age-adjusted percentages (standard error) of adults aged 20–79 years taking prescription medications for chronic
obstructive pulmonary disease, by obstructive impairment and self-reported chronic obstructive pulmonary disease, National
Health and Nutrition Examination Survey 2007–2010.
OI-PFT +, COPD-SELF + OI-PFT +, COPD-SELF 2 OI-PFT 2, COPD-SELF + OI-PFT 2, COPD-SELF 2
N* 100 971 147 6669
Any short-acting agent{ 68.1 (3.9) 8.1 (1.8) 27.4 (5.7) 1.9 (0.2)
Any inhaled long-acting beta-2 agonists` 16.3 (8.9) 2.9 (0.8) 11.3 (3.0) 1.1 (0.2)
Any inhaled corticosteroid1 23.6 (9.7) 3.8 (1.0) 12.6 (3.0) 1.5 (0.2)
Tiotropium –" –" –" –"
Methylxanthines? –" –" –" –"
Any medication for COPD 72.6 (3.6) 9.6 (1.8) 29.1 (5.8) 2.8 (0.2)
COPD= chronic obstructive pulmonary disease; OI = obstructive impairment; PFT = pulmonary function test.
*Sample sizes represent unweighted numbers.
{Albuterol, fenolterol, levalbuterol, metaprotenerol, pirbuterol, terbutaline, ipratropium.
`Salmetrol, formoterol, arformoterol.
1Beclomethasone, budenoside, flunisolide, fluticasone, triamcinolone.
?Aminophylline, theophylline.
"Relative standard error $40%.
doi:10.1371/journal.pone.0095305.t006
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budesonide in 2006. The classes of all of these agents showed
strong increases during the study period. A previous analysis of
data from the National Ambulatory Medical Care Survey from
1995 to 2004 showed that prescriptions for oral corticosteroids in
men and methylxanthines in men and women had decreased but
prescriptions for anticholinergic agents had increased [9]. As in
other studies, we found that short-acting agents, principally
SABAs, were the most commonly used medications by 2009–
2010 [10,11]. In our study, the next most frequently used
medications were combination products containing LABAs and
a corticosteroid (13.7%) followed by ICS (8.0%).
Our analysis of sociodemographic correlates of medication use
indicated that there were no statistically significant differences in
the use of these medications between white and African American
adults. However, Mexican American adults with COPD were less
likely than whites to use major groups of medications. Because
little information about health disparities involving treatment for
COPD in Hispanic populations appears to have been published,
our findings require confirmation. Reduced access to health care,
language barriers, and cultural beliefs are possible factors that can
affect treatment for COPD among Mexican Americans [12].
In our study, considerable percentages of adults with self-
reported COPD or with COPD defined by spirometry did not
divulge having medications used to treat COPD. Because of the
cross-sectional nature of the survey, the presence of symptoms and
use of medications were collected at a single point in time,
precluding establishing the temporal sequence of symptom onset
and instituted treatment. Other studies have also found low rates
of pharmacotherapy among patients with COPD [13–15]. In the
United States, an analysis of the PharMetrics database from 2004–
2005 showed that 59.1% of commercial patients and 66.0% of
Medicare patients with COPD were not prescribed any COPD
medications [15]. In a Japanese study, 31% of patients with
moderate to severe COPD did not receive adequate treatment
(Takahashi 2003) [13]. In a study from Denmark, only 42% of
patients who were identified as having COPD in a population
study were receiving treatment in the year following their
examination (Ingebrigtsen 2013) [14].
Raising awareness of COPD in the general population and
clinical community is a theme that echoes with regularity in the
medical literature and is critical to bringing patients with COPD
into the medical system so that appropriate treatment of their
condition can be initiated [16–18]. High levels of undiagnosed
COPD or misdiagnosis of the disease likely account for some of the
suboptimal rates of treatment among people with COPD [19]. In
our study, we observed that a high percentage of adults whose
spirometric examination indicated an obstructive impairment did
not report having COPD. Although in a survey of British general
practitioners, levels of confidence in their ability to diagnose and
manage COPD were quite high [20], estimates suggest that about
half of patients with COPD may not be diagnosed [21,22].
Once diagnosed, other factors may influence the rate of
medication use by people with diagnosed COPD shown in this
and other studies. First, many people with COPD may not have
received treatment as recommended by prevailing guidelines
because physicians may be unaware or unfamiliar with guidelines
or because some may not follow the guidelines [23,24]. Although
the reasons why physicians may not follow prevailing guidelines
are not entirely clear, many aspects of guidelines were developed
on the basis of key clinical trials that often excluded participants
with comorbidities or other characteristics relevant to daily clinical
practice [25]. A literature review of potential barriers to physician
adherence to clinical practice guidelines in general identified
several barriers: familiarity, agreement, self-efficacy, outcome
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expectancy, ability to overcome inertia of previous practice, and
absence of external barriers to perform recommendations [26].
When presented with several COPD case studies, however, many
practitioners tended to gravitate towards a diagnosis of cardiac
rather than pulmonary origin [20]. By increasing the detection
rate of COPD, which would presumably result in increased
treatment, the treatment rate among all people with COPD would
be increased. Other studies specific to adherence to COPD
guidelines noted that agreement with recommendations, low self-
efficacy, perceived outcome expectancy, resource availability, and
time constraints were barriers to physician adherence to guidelines
for COPD [27,28].
Empowering patients with COPD may boost the percentage of
patients who are receiving appropriate treatment for COPD and
contribute to improving the course of their disease. Public health
strategies to empower patients with COPD [29] complemented by
clinical strategies founded in the chronic care model that seek to
enhance patient self-management may serve to increase the
percentages of adults with COPD on appropriate treatment [30].
Adherence to prescribed medications is suboptimal among
patients with COPD [15]. Patient-associated factors that may
impede adherence to prescribed treatments may include cost,
complexity of treatment regime, presence of comorbidities
requiring treatment, side effects, adverse events, treatment fatigue,
and other innate factors. Understanding the issues is a prerequisite
to developing sound interventions to maximize adherence.
In the PharMetrics database, adherence varied from 52.3% for
short-acting anticholinergic agents to 82.2% for leukotriene
modifiers among commercial patients and from 51.8% for short-
acting anticholinergic agents to 85.2% for leukotriene modifiers
among Medicare patients [15]. An analysis of another adminis-
trative database in the United States showed that adherence as
measured by the proportion of days covered was highest for
medications that are supposed to be used once per day compared
to medications that are to be taken twice, three times, and four
times per day [31]. Furthermore, adherence declined steadily from
3 months post initiation to 12 months post initiation in each
category of frequency of use.
Our results are subject to several limitations. First, the small
number of survey participants with COPD limited our ability to
stratify the data or to examine specific medications in most
instances. Second, a number of participants had a reversible
airflow limitation because we used prebronchodilator spirometry
results. Third, some proportion of patients with self-reported
COPD do not meet spirometric criteria for obstructed airflow. For
the years 2007–2010, 34.8% of participants with self-reported
COPD had an obstructive impairment, and thus, the level of
undertreatment of people with self-reported COPD may not be as
substantial as it appears. If the proportion of adults with self-
reported COPD who did not have an obstructive impairment
based on spirometry remained reasonably constant over time,
however, the trends in medication usage likely reflect the direction
of actual trends in the population. Fourth, we did not have access
to data that would have allowed us to establish the reasons why
certain medications were prescribed or the route of administration.
Knowing the reason for use is especially critical for medications
with a wide range of uses such as oral corticosteroids.
In conclusion, substantial changes in the use of medications to
treat airflow limitations among adults with COPD occurred from
1999–2000 to 2009–2010, and a low percentage of adults with self-
reported COPD reported having medications used to treat
COPD. Given the demonstrated benefits of treatment, improving
treatment is a high public health priority as envisioned in the
Public Health Strategic Framework for COPD Prevention [32].
Furthermore, these findings provide important information to
guide national education efforts such as the National Heart, Lung,
and Blood Institute’s COPD: Learn More, Breathe Better
campaign [33]. Such efforts could enhance the ability of health
professionals to increase the delivery of optimal treatment of
persons diagnosed with COPD to optimum treatment.
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